Similar glycemic control and lower instances of hypoglycemia may be achieved with glargine 300 U/mL (Gla-300) vs glargine 100 U/mL (Gla-100) in individuals with type 2 diabetes (T2D) despite T2D duration, age at T2D onset, and body mass index (BMI), according to a study published in Diabetes Therapy.
Researchers analyzed data from past phase 3 studies, concentrating on 2496 people with T2D who received either basal and prandial insulin, basal insulin with oral antihyperglycemic drugs, or no insulin. With subgroups, they investigated glycated hemoglobin (HbA1c), hypoglycemia, body weight changes, insulin dose, age at onset of T2D, and duration of T2D.
Reduction in HbA1c and severe hypoglycemic events was similar regardless of insulin types across all subgroups. Mild heterogeneity of treatment effect was observed between participants with T2D for less than 10 years and those with a T2D diagnosis of at least 10 years (P =.006), in favor of Gla-300 regardless of T2D duration. Similar results were observed by dose of insulin. Severe hypoglycemia and body weight changes were also not a factor.
The results indicate that glycemic control with Gla-300 and Gla-100 is similar despite age, age of T2D onset, and BMI. The researchers suggest that it is reassuring to know that these “are not important influencing factors.”
Disclosure: Multiple authors declare affiliations with pharmaceutical companies. Please see reference for a full list of disclosures.
Twigg SM, Escalada J, Stella P, et al. Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis [published online September 10, 2018]. Diabetes Ther. doi: 10.1007/s13300-018-0498-x